Infant post-exposure prophylaxis Which drugs should be used for infant post-exposure prophylaxis and for how long? Should PCP prophylaxis

be administered to the neonate? Infant feeding Is an update required to the BHIVA position statement? If mother breastfeeds, how frequently should mother and baby be monitored and what tests should be used? How should infants be fed (breast or bottle)? Infant testing What tests should be undertaken on the neonate and when? Study design: systematic reviews (SRs), randomized control trials (RCTs), observational, risk, economic Population: HIV-positive women Intervention: starting antiretroviral therapy during pregnancy Comparator: none Outcomes: death, AIDS, non AIDS co-morbidities, maternal obstetric morbidity, infant mortality

and morbidity, mother-to-child HIV transmission, drug resistance Raf kinase assay HIV monitoring What baseline tests should be recommended for HIV-positive women? How often should they be repeated? How should we investigate Navitoclax research buy and manage abnormal liver function in pregnancy Sexual health When should we recommend sexual health screening and how often? How should we manage genital infections in HIV-positive pregnant women? Component Description Review area Safety and efficacy of antiretrovirals in pregnancy Objectives To assess the benefits and risks of ART in pregnancy Populations HIV-positive women Urease who are pregnant, HIV-positive women of child bearing age Interventions Antiretroviral therapy (all drugs) Comparisons/aspects covered by search

Between antiviral regimens and historical data where appropriate Outcomes To be decided by Writing Groups Study designs SRs, RCTs, observational studies, risk, economic Exclusions Animal studies, letters, editorials, comments, case reports, non-English studies How the information was searched Databases: Medline, Embase, Cochrane Library, Conference abstracts 2008–2013 Language: restrict to English only Date parameters: –July 2013 Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 973–981. Tariq S, Townsend CL, Cortina-Borja M, Duong T, Elford J, Thorne C et al. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000–2009. J Acquir Immune Defic Syndr 2011; 57: 326–333. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25: 2301–2304.